HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gut microbiota-derived 12-ketolithocholic acid suppresses the IL-17A secretion from colonic group 3 innate lymphoid cells to prevent the acute exacerbation of ulcerative colitis.

Abstract
Intestinal microbiota dysbiosis and metabolic disruption are well-known as the primary triggers of ulcerative colitis (UC). However, their role in regulating the group 3 innate lymphoid cells (ILC3s), which are essential for intestinal health, remains unexplored during the development of disease severity. Here, our results showed that the microbiota structure of patients with severe UC (SUCs) differed from those with mild UC (MiUCs), moderate UC (MoUCs), and healthy controls (HCs). Microbes producing secondary bile acids (SBAs) and SBAs decreased with the aggravation of UC, and a strong positive correlation existed between them. Next, fecal microbiota transfer was used to reproduce the human-derived microbiota in mice and decipher the microbiota-mediated inflammatory modulation during an increase in disease severity. Mice receiving SUC-derived microbiota exhibited enhancive inflammation, a lowered percentage of ILC3s, and the down-regulated expressions of bile acid receptors, including vitamin D receptor (VDR) and pregnane X receptor (PXR), in the colon. Similar to clinical results, SBA-producing microbes, deoxycholic acids (DCA), and 12-ketolithocholic acids (12-KLCA) were diminished in the intestine of these recipients. Finally, we compared the therapeutic potential of DCA and 12-KLCA in preventing colitis and the regulatory mechanisms mediated by ILC3s. 12-KLCA but not DCA represented a strong anti-inflammatory effect associated with the higher expression of VDR and the lower secretion of IL-17A from colonic ILC3s. Collectively, these findings provide new signatures for monitoring the acute deterioration of UC by targeting gut microbiota and bile acid metabolism and demonstrate the therapeutic and preventive potential of a novel microbiota-derived metabolite, 12-KLCA.
AuthorsNa Li, Peiguang Ma, Yalan Li, Xuekai Shang, Xinmei Nan, Lei Shi, Xiao Han, Jiajing Liu, Yanfei Hong, Qiuyi Li, Jiaqi Cui, Junxiang Li, Guiying Peng
JournalGut microbes (Gut Microbes) Vol. 15 Issue 2 Pg. 2290315 (Dec 2023) ISSN: 1949-0984 [Electronic] United States
PMID38062857 (Publication Type: Journal Article)
Chemical References
  • 12-ketolithocholic acid
  • Bile Acids and Salts
  • Dextran Sulfate
  • Interleukin-17
Topics
  • Animals
  • Humans
  • Mice
  • Bile Acids and Salts (metabolism)
  • Colitis (metabolism)
  • Colitis, Ulcerative (drug therapy)
  • Colon (metabolism)
  • Dextran Sulfate
  • Disease Models, Animal
  • Gastrointestinal Microbiome
  • Immunity, Innate (drug effects)
  • Interleukin-17 (metabolism, pharmacology)
  • Lymphocytes (drug effects)
  • Mice, Inbred C57BL

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: